Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Decline Accept
Home › Fund moves › Edesa Biotech › Rubric Capital Management LP cut its EDSA stake below 5% (4.6%) Fund moves
Why it stands out The holder reported owning less than 5%, which ends its duty to keep reporting this stake.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
All the details
Dates, kept separate
Date of the event that required the filing Sep 30, 2026
Reporting period Not applicable
Filed with the SEC Nov 16, 2026 passive 5% holder
Context Change vs prior quarter Undefined
Compared with the manager's prior 13F
Tracked managers with the same change NaN
For the same quarter
0001104659-26-128312
Data quality Verified: identifiers matched exactly
Around the same time Fund moves
A Schedule 13G is filed by holders above 5% who say they will not try to influence the company. Index funds and large asset managers file most of them.
Fund moves
A Schedule 13G is filed by holders above 5% who say they will not try to influence the company. Index funds and large asset managers file most of them.
Fund moves
The holder reported owning less than 5%, which ends its duty to keep reporting this stake.
The story around this disclosure Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
Aug 13, 2026 Company filing · Form 8-K · Results Reported its results Aug 19, 2026 Company filing · Form 8-K · Material agreement, Other news Signed an important agreement, and reported other company news What came next Oct 23, 2026 Company filing · Form 8-K · Executive change Changed a top executive or board member “On October 23, 2026, the Board of Directors (the “Board”) of Edesa Biotech, Inc. (the “Company”), upon the recommendation of the Compensation Committee of the Board, approved increases in the annual base salaries of Dr. Pardeep Nijhawan, the Company’s Chief Executive Officer, from $357,696 to $657,423, Dr. Michael Brooks, the Company’s President, from $335,340 to $591,681, and Peter Weiler, the Company’s Chief…” Nov 4, 2026 5% stake Millennium Management LLC reported a passive stake (13G) of 8.7% Nov 8, 2026 Company filing · Form 8-K · Material agreement, Agreement ended Signed an important agreement, and ended an important agreement (and 1 more item) Nov 12, 2026 5% stake Adage Capital Management, L.P. reported a passive stake (13G) of 7.8% Nov 16, 2026 5% stake Sirenia Capital Management LP reported a passive stake (13G) of 9.9% Nov 16, 2026 5% stake StemPoint Capital LP reported a passive stake (13G) of 9.9% Nov 16, 2026 5% stake Rubric Capital Management LP reported a passive stake (13G) of 4.6% Nov 16, 2026 5% stake Boxer Capital Management, LLC reported a passive stake (13G) of 6.9% Nov 16, 2026 5% stake Perceptive Advisors LLC reported a passive stake (13G) of 4.2%